-transparent.png){kind=logo}
The metabolism of the carcinogenic pentacyclic azaaromatic compound, dibenz[a,j]acridine, has been examined in liver microsomal incubations using preparations from 3-methylcholanthrene-pretreated Wistar rats. Using authentic synthetic standards, u.v. spectroscopy and mass spectrometry, the following were proved to be metabolites: trans-5,6-dihydro-5,6-dihydroxydibenz[a,j]acridine, trans-3,4-dihydro-3,4-dihydroxydibenz[a,j]acridine, dibenz[a,j]acridine-5,6-oxide, 3-hydroxydibenz[a,j]acridine and 4-hydroxydibenz[a,j]acridine. The 3,4-dihydrodiol appeared to be the major metabolite. The secondary metabolites were also examined and evidence is presented for the additional formation of dibenz[a,j]acridine-5,6,8,9-dioxide, tetrols, diol epoxides and phenolic dihydrodiols.
J H Gill, and
C C Duke, and
C A Rosario, and
A J Ryan, and
G M Holder
August 1987,
Carcinogenesis,
J H Gill, and
C C Duke, and
C A Rosario, and
A J Ryan, and
G M Holder
January 1992,
Chemico-biological interactions,
J H Gill, and
C C Duke, and
C A Rosario, and
A J Ryan, and
G M Holder
December 1983,
IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans,
J H Gill, and
C C Duke, and
C A Rosario, and
A J Ryan, and
G M Holder
March 1995,
Carcinogenesis,
J H Gill, and
C C Duke, and
C A Rosario, and
A J Ryan, and
G M Holder
November 1977,
Biochemical and biophysical research communications,
J H Gill, and
C C Duke, and
C A Rosario, and
A J Ryan, and
G M Holder
November 1990,
Carcinogenesis,
J H Gill, and
C C Duke, and
C A Rosario, and
A J Ryan, and
G M Holder
May 1996,
Drug metabolism and disposition: the biological fate of chemicals,
J H Gill, and
C C Duke, and
C A Rosario, and
A J Ryan, and
G M Holder
June 1972,
Chemical & pharmaceutical bulletin,
J H Gill, and
C C Duke, and
C A Rosario, and
A J Ryan, and
G M Holder
September 1985,
Cancer letters,
J H Gill, and
C C Duke, and
C A Rosario, and
A J Ryan, and
G M Holder
June 1978,
Cancer letters,
